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Monoclonal antibodies that bind and inhibit nerve growth factor (NGF) have demonstrated both, good
analgesic efﬁcacy and improvement in function in patients with osteoarthritis (OA). Despite initial
promising data, trials in OA had been suspended by the Federal Food and Drug Administration (FDA) due
to concerns over accelerated rates of OA progression. Imaging will play a crucial role in future clinical
trials to deﬁne eligibility of potential participants and to monitor safety during the course of these
studies. This will require baseline and frequent follow-up radiographs of both, the index joints and other
large weight bearing joints to identify subjects at risk prior inclusion and on study so treatment can be
discontinued.
This imaging overview in the form of an atlas describes and illustrates potential exclusionary joint
imaging ﬁndings at eligibility and potential adverse joint events on radiography and magnetic resonance
imaging (MRI) in studies investigating a-NGF compounds. The overarching goal of this atlas is to facilitate
trial design and to promote a common language and understanding between potential expert readers.
This ﬁrst section of the atlas will focus on knee joint speciﬁc ﬁndings that are relevant to a-NGF studies.
© 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Monoclonal antibodies that bind and inhibit nerve growth fac-
tor (NGF) have demonstrated both, good analgesic efﬁcacy and
improvement in function in patients with osteoarthritis (OA) and
low back pain1e5. Despite initial promising data, trials in OA had
been suspended in 2010 by the Federal Food and Drug Adminis-
tration (FDA) due to concerns over accelerated rates of OA pro-
gression (i.e., rapid progressive osteoarthritis e RPOA) to total joint
replacement particularly in the large joints of the lower limb6,7. The
observations about adverse events in tanezumab studies, one of the
a-NGF compounds under investigation, lead to a report on the
process and results of the adjudication of these events8 These
adverse events were observed in patients using NGF-inhibitors
alone, and more commonly in combination with non-steroidalF.W. Roemer, Department of
GH Building, 3rd Floor, 820
-4954; Fax: 1-617-638-6616.
mer@uk-erlangen.de, frank.
lf of Osteoarthritis Research Societanti-inﬂammatory drugs (NSAIDs) suggesting that the cumulative
analgesic effect of two separate classes of drugs prompted patients
to permit increased joint loading lacking the usual pain that would
limit such pathologic stress on an already damaged joint5,8. The
authors further reported a signiﬁcant doseeresponse relationship
between incident RPOA and increasing doses of tanezumab, which
was greater when tanezumab was given in combination with
NSAIDs8.
Since anti(a)-NGF therapies offer potential as the ﬁrst new class
of analgesics for many years, future studies of a-NGF compounds
will require rigorous safety criteria. Imaging will play a crucial role
in future clinical trials to deﬁne eligibility of potential participants
and to monitor safety during the course of these studies. This will
require baseline and frequent follow-up radiographs of both, the
index joints and other large weight bearing joints to identify sub-
jects at risk for RPOA and identify subjects on study with adverse
events such as RPOA Type I or II so treatment can be discontinued.
Additional magnetic resonance imaging (MRI) examinations will be
important during the course of a study in cases of unexpected joint
pain or swelling or in cases of discrepancy between clinical
symptoms, mainly pain and radiographic ﬁndings6.y International.
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to describe and illustrate potential exclusionary joint imaging
ﬁndings at eligibility and potential adverse joint events on radi-
ography and MRI in studies investigating a-NGF compounds. The
overarching goal of this atlas is to facilitate trial design and to
promote a common language and understanding betweenpotential
expert readers. This ﬁrst section of the atlas will focus on knee joint
speciﬁc ﬁndings that are relevant to a-NGF studies.
Methods
This atlas is based on eight in-person and 20þ teleconference
meetings of four experienced musculoskeletal radiologists (FWR,
CH, KH, AG) and a senior imaging expert (CGM) representing a
contract research organization (CRO) active in a-NGF studies to
deﬁne potential eligibility and safety ﬁndings relevant for a-NGF
clinical trials. 400þ baseline and follow-up radiographic and MRI
image examples of knee joints were reviewed in consensus to
deﬁne the most relevant and characteristic imaging ﬁndings of
entities that may be encountered during a-NGF studies at screening
or during the course of a study. Images for this atlas were derived
from personal teaching and training ﬁles of these radiologists and
partly from a Pﬁzer library of knee radiographs obtained during the
course of the tanezumab program. As the terminology for several of
the potentially encountered ﬁndings is not uniform, the following
section will brieﬂy deﬁne those pathologic conditions for the pur-
pose of this atlas.
The term osteonecrosis in the context of this atlas is used for a
focal circumscribed or extended region of infarcted bone. “Avas-
cular necrosis” and “bone infarct” are commonly used in synony-
mous fashion. Any focus of infarcted bone regardless of its location
within the bone will be deﬁned as osteonecrosis. The term “spon-
taneous osteonecrosis of the knee” (also called SONK or SPONK)
will be summarized under subchondral insufﬁciency fracture (SIF),
reﬂecting current etio-pathologic understanding9,10.
RPOA Type 1 is deﬁned as rapid loss of joint space width (which
is deﬁned as 2 mm or other protocol-speciﬁc cut-off) within
approximately 1 year without evidence of bone loss or destruction.
The diagnosis can only be established whenever prior images are
available to allow longitudinal assessment11.
RPOA Type 2 is used for a condition of abnormal bone loss or
destruction in a short period of time, including limited or total
collapse of at least one subchondral surface that is not a feature of
conventional advanced OA12.
A SIF may stabilize or heal with minor deformity or no defor-
mity, or may progress to complete subchondral collapse. The latter
is often referred to as SONK or SPONK in the knee joint13. For the
purposes of this atlas, the term “SONK” will not be used as it is
considered to be part of the spectrum of SIF and not a separate
condition. SIF may be seen on radiography as a focal area of sub-
chondral osteopenia and once articular surface deformities are
present. MRI is more sensitive to detect early manifestations of SIF,
once these are still potentially reversible and is able to deﬁne
prognosis14.
Atrophic osteoarthritis is characterized by joint space narrowing
(JSN) without relevant osteophyte formation and absence of ero-
sions or other radiographic signs of inﬂammatory arthritis15,16. In
some cases, RPOA Type I is preceded by an atrophic OA appearance;
therefore subjects exhibiting radiographic atrophic OA at the
screening visit are commonly excluded from entering any study.
Severe malalignment may be a marker of more rapid OA pro-
gression and thus, may be an additional diagnosis of exclusion at
eligibility. Cut-off values of severe malalignment are not deﬁned in
the literature andmay vary. Commonly used cut-offs are between 6
or 10 varus or valgus in the anterioreposterior direction17.Large areas of bone marrow edema without fracture line as
visualized on ﬂuid-sensitive fat-suppressed MRI are usually painful
conditions and will explain incident or worsening of pain in a
number of subjects18,19. These can be part of the OA disease process
especially if they are observed in a subchondral location20. They
may also be the result of more acute overloading leading to a stress
reaction that manifests itself as a large area of bonemarrow edema,
but does not show a characteristic hypointense fracture line21.
“Idiopathic transient bone marrow edema”will present in identical
fashion22,23.
Diagnoses of exclusion for eligibility are those that potentially
increase the risk of RPOA Type I or II. These are pre-existing
atrophic OA and RPOA, SIF and potentially severe malalignment
of the knee. Additional diagnoses of exclusion for eligibility may
be severe chondrocalcinosis, which may be observed in associa-
tion with OA24. However, the threshold deﬁnition for “severe”
may vary between studies and the literature is not unequivocal in
regard of rates of progression25. Other arthropathies, e.g., rheu-
matoid arthritis, gout, systemic metabolic bone or joint diseases
are reasons for excluding subjects from entering a trial and if
detected while on-study, a reason to recommend discontinuation
of treatment but may vary between studies. These also include
primary or metastatic malignant tumors consistent with grades 2
and 3 of the Lodwick classiﬁcation26,27. In addition, fractures
(stress, traumatic, pathologic) detected by either radiography or
MRI are reason to exclude a subject from entering a trial
regardless of cause of fracture. Fractures are deﬁned by a visible
fracture line.
Diagnoses relevant for safety after enrollment (i.e., joint safety
ﬁndings) are RPOA Types I and II, SIFs, osteonecrosis and pathologic
fractures plus incidental ﬁndings of the entities described above.
Several of these diagnoses have non-speciﬁc ﬁndings on the
radiograph or cannot be detected radiographically in early stages.
Thus, in cases of inconclusive or suspicious radiography an addi-
tional MRI examination will commonly be acquired to rule out or
conﬁrm some of these diagnoses especially in early stages and thus,
MRI ﬁndings will be presented in addition.
The image acquisition process being deﬁned in this atlas is that
potential participants will be screened by radiography for eligibility
criteria, using a conservative approach to allow subjects being
included into the study. Once included into a study, radiography
will still be the ﬁrst line imaging approach, but MRI scans of any or
all joints may be requested if needed (i.e., “for cause”, commonly
requested due to equivocal radiographic ﬁndings or discrepancies
between radiography and clinical symptoms).
The term “adverse event(s)” is used throughout this atlas in
relationship to clinical trials as deﬁned by the FDA: “Adverse event
means any untowardmedical occurrence associated with the use of
a drug in humans, whether or not considered drug related.”28 No
causality or level of whether this is a “serious” adverse event is
being attributed in this atlas.
The radiographic imaging acquisition protocol that is being
recommended for the knee in aNGF studies is the posteri-
oreanterior view in a modiﬁed Lyon-Schuss technique29e31. This
technique has been shown to provide the best precision
for evaluating JSN in clinical trials32,33. The MRI protocol should
be a standard clinical protocol or an abbreviated protocol con-
sisting of at least a sagittal and coronal proton density or T2-
weighted fat suppressed sequence and a coronal or sagittal T1-
weighted non-fat suppressed sequence. The use of 1.5 T or 3 T
large bore MRI is recommended for assessment of joints in aNGF
studies. 1.0 T or 1.5 T extremity scanners may be used alterna-
tively but are only applicable to image the knee joint and not
other joints commonly assessed in aNGF studies such as the hip
or shoulder.
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The radiographic appearance of atrophic osteoarthritis, one of
the diagnoses of exclusion at eligibility is depicted in Fig. 1.
Figure 2 exempliﬁes a case of RPOA Type 1 over the course of 18
months. The catastrophic events of two cases of RPOA Type II are
illustrated in Fig. 3. Several examples of the spectrum of SIFs with
or without focal areas of necrosis are illustrated in Figs. 4e8.
Characteristic MRI ﬁndings of osteonecrosis (or bone infarcts) are
shown in Fig. 9. Examples of large areas of subchondral bone
marrow edema in the context of OA or due to mechanical overload
(i.e., stress reaction) without a fracture are shown in Fig. 10.
Figure 11 represents an example of transitory migrating bone
marrow edema syndrome, a self-limiting entity that may affectseveral joints over time. Other arthropathies may be potential
diagnoses for exclusion at screening and include severe chon-
drocalcinosis (Fig. 12), inﬂammatory arthritis, pigmented villo-
nodular synovitis (PVNS), or fracture, which may also be safety
endpoint on study (Figs. 13 and 14). Primary or secondary malig-
nant bone tumors are a diagnosis of exclusion while some tumor-
like entities such as enchondroma, non-ossifying ﬁbroma or gan-
glion cysts may not. Some of these entities are shown in Figs. 15
and 16. Finally, severe malalignment may be considered a risk
factor for more rapid progression and thus, may be an exclu-
sionary diagnosis at eligibility. An example of severe varus and
valgus malalignment is shown in Fig. 16. This atlas is not illus-
trating all potential diagnoses that might be relevant for eligibility
or safety but covers the large majority of these.
Fig. 1. Different examples of atrophic osteoarthritis. A. Anterioreposterior (a.p.) radiograph shows deﬁnite (grade 1 according to the Osteoarthritis Research Society International
(OARSI) atlas) JSN at the medial tibio-femoral compartment (arrows) without osteophyte formation. B. Moderate JSN is depicted (arrows e grade 2 according to the OARSI atlas)
with only minimal osteophyte formation at the lateral tibia. C. Severe JSN is shown in this example (large arrows) with presence of only a small osteophyte at the lateral tibia (small
black arrow) and another very small osteophyte at the medial tibial margin (short white arrow). As some remaining joint space is still present, this knee qualiﬁes for a grade 2
according to OARSI. D. Another example of advanced grade 2 JSN is shown in this radiograph (arrows). No osteophytes are observed.
Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised. Osteoarthritis Cartilage. 2007;15 Suppl A:A1-56.
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Fig. 2. RPOA Type I over the course of 18 months. A. Baseline radiograph shows normal medial and lateral joint space width. B. 6 months follow-up radiograph depicts deﬁnite
medial JSN (arrows) with persistent absence of osteophytes medially. C. Radiograph acquired 8 months after image B shows progressive loss of joint space medially (arrows). D. 4
months later bone-to-bone appearance with complete obliteration of joint space at the medial compartment is observed (arrows).
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Fig. 3. RPOA Type II over a period of 9 months. A. Baseline radiograph shows deﬁnite osteophytes at the medial tibial and femoral margin (arrows) and a regular articular surface
contour. B. 9 months later deformity of the medial femoral and tibial articular surface is noted. In addition there is collapse especially of the tibial plateau. Consequent varus
deformity is observed. C. Another knee exhibits minimal medial joint space width at baseline without relevant osteophyte formation. D. Follow-up image 10 months later shows
marked deformation of the medial compartment articular surface consistent with RPOA Type II.
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Fig. 4. SIF and subchondral collapse (also known as SPONK). A. Baseline image shows mild medial JSN on the a.p. knee radiograph without signs of osteophyte presence. B. Follow-
up image 10 months later reveals femoral surface deformity (arrows) as a sequelae of SIF. A corresponding MRI at baseline (not shown) exhibited diffuse bone marrow edema, which
cannot be visualized by radiography. C. Another example shows medial femoral subchondral collapse as the result of SIF with mild depression of the femoral surface (arrow). D.
Radiograph of advanced subchondral collapse secondary to SIF with deformity of the medial femoral surface (arrow). Note marked subchondral sclerosis (asterisk) reﬂecting
structural remodeling in the subchondral bone due to altered local biomechanical loading.
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Fig. 5. Resolution of SIF over time. A. Baseline sagittal fat suppressed T2-weighted MR image shows an extensive area of diffuse bone marrow edema in the lateral femoral condyle
(arrows). B. Follow-up proton density-weighted fat suppressed image 4 months later depicts marked regression of bone marrow edema but a persistent focus of subchondral
hyperintensity (arrow). C. Corresponding T1-weighted image exhibits edema-like changes as hypointensities (long arrows). In addition, there is a subchondral fracture line (short arrow).
Note intact articular chondral surface. D. Follow up proton density-wieghted fat suppressed image another 8 months later shows complete resolution of signal changes and fracture. All
of these changes visualized on MRI were occult on radiography.
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Fig. 6. SIF with necrosis and unfavorable outcome. A. Coronal T1-weighted MR image shows an area of subchondral ill-deﬁned hypointensity consistent with bone marrow edema
(arrows). B. Corresponding proton density-weighted fat suppressed image depicts edema-like signal as diffuse hyperintensity (large arrows). In addition there is a focal area of
hypointensity directly adjacent to the subchondral plate representing subchondral necrosis (small arrow). Articular surface is at risk for collapse. C. Another knee shows a more
advanced stage of SIF with a large area of subchondral necrosis (thick arrows) and surrounding diffuse bone marrow edema-like alterations (thin arrows). D. Corresponding coronal
proton density-weighted fat suppressed image depicts focal collapse of articular surface (arrows) and extensive edema-like signal in the medial femoral condyle.
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Fig. 7. SIF without necrosis and favorable outcome. A. Proton density-weighted fat suppressed image shows diffuse subchondral bonemarrow edema and a small fracture line (arrow)
directly adjacent to the subchondral plate. No area of focal hypointensity representing possible necrosis is seen. B. T1-weighted image of same patient depicts fracture line in superior
fashion (arrows). C. Another case shows diffuse bone marrow edema on this fat suppressed proton density-weighted image but no fracture line. D. Corresponding T1-weighted image
shows discrete but deﬁnite subchondral fracture (arrows) in the subchondral bone reﬂecting the higher sensitivity of T1-weighted imaging for the detection of fractures on MRI.
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Fig. 8. SIF with necrosis and beginning collapse of articular surface. A. Sagittal proton density-weighted fat suppressed MR image shows diffuse bone marrow edema in the medial
femoral condyle and a focal area of subchondral hypointensity representing necrosis (arrow). Articular surface is at risk of collapse. B. Corresponding coronal proton density-
weighted fat suppressed image shows extent of the lesion in the medialelateral direction (arrows). C. Another case (T1-weighted image) exhibits less difuse edematous
changes but a subchondral hypointense impaction representing necrosis (arrow). D. Corresponding fat suppressed proton density-weighted image superiorly exhibitis edema and
also visualizes subchondral area of necrosis (arrow). E. T2-weighted follow-up image 3 months later shows beginning demarcation of necrotic area (arrows) with ﬂuid-like signal
beneath the fracture line (small arrow). F. Corresponding ﬂuid sensitive fat suppressed image conﬁrms this ﬁnding showing the fracture line (long, thin arrows) and ﬂuid beneath
the fracture (large arrow). In addition, note beginning articular surface deformity (short arrows).
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Fig. 9. Osteonecrosis. A. Coronal proton density-weighted fat suppressed MR image shows areas of osteonecrosis in the medial femur (thick arrows) and in the metaphyseal tibia
(thin arrows). These are usually incidental ﬁndings on MR imaging. Note characteristic serpiginous hyperintense demarcation and central areas of fat equivalent signal. B. Another
case of large epiphyseal osteonecrosis in the lateral femur (arrows). Note fat equivalent signal in the center of lesions (asterisk). Osteonecrosis can be a source of pain, may weaken
bone and lead to articular surface collapse, especially when located epiphyseally. C. Coronal T1-weighted mage shows typical metaphyseal osteonecrosis (arrows) with central fat-
like signal (asterisk). D. Another case of tibial osteonecrosis (white arrow) and concomitant ﬁnding of insufﬁciency fracture (black arrow).
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Fig. 10. Large areas of bone marrow edema. A. Subchondral bone marrow lesions (BMLs) are a common ﬁnding in OA knees and are associated with pain and more rapid structural
progression. Sagittal proton density-weighted fat suppressed image depicts large subchondral areas of diffuse hyperintensity in the medial femur (long arrows) and tibia (short
arrows) representing BMLs. B. Large diffuse subchondral hyperintensity changes may also be observed as a consequence of mechanical overload as seen in this case in the medial
tibia (asterisk) after extensive running. Continued loading may potentially lead to SIF. C. Unexplained pain with no explanatory ﬁnding on X-ray may be caused by transient bone
marrow edema syndrome. D. Corresponding coronal fat suppressed proton density-weighted MRI shows large area of diffuse bone marrow edema in the medial femoral condyle
(arrows). This is commonly a self-limiting condition that may potentially progress to SIF if loading continues.
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Fig. 11. Transient migratory bone marrow edema syndrome. A. At initial presentation this patient complained about diffuse pain in the left knee. A large area of bone marrow edema
without fracture was observed in the medial femur. B. While pain receded on the left, incident pain in the right knee was reported 7 months later. A large area of bone marrow
edema was seen in the medial femoral condyle of the right knee. C. After complete resolution of symptoms, 12 months later incident pain was reported in the left hindfoot. Now
bone marrow edema was seen in the calcaneus (arrows). D. After 30 months of initial complaints in the left knee, a diagnosis of bone marrow edema (BME) was established in the
left talus. Such a course is rare but not unusual. Complete resolution of all symptoms was observed after 3 years.
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Fig. 12. Chondrocalcinosis is common in patients with OA and is a ﬁnding commonly to be expected in a-NGF patients. In some aNGF programs under development, severe
chondrocalcinosis may be a reason for exclusion at eligibility due to potentially increased risk for on-study adverse events. A. Anterioreposterior radiograph shows mild chon-
droclacinosis in the medial (black arrows) and lateral (white arrow) tibiofemoral joint. B. Another knee exhibits mild chondrocalcinosis in the lateral tibiofemoral joint only
(arrows). C. Mild to moderate intraarticular calciﬁcations representing chondrocalcinosis are seen in this example medially (white arrows) and laterally (black arrows). D. Example
of severe chondrocalcinosis with marked calciﬁcations in the lateral tibiofemoral joint space (white arrows). In addition there is a so-called Stieda-Pellegrini fragment at the medial
femoral condyle reﬂecting remote trauma to the medial collateral ligament (black arrow).
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Fig. 13. Other arthropathies may be reasons for exclusion at eligibility and during the course of a study. These may include inﬂammatory arthritis and fractures. A. Radiograph
shows typical bone erosion at the medial tibial plateau (arrow) consistent with rheumatoid arthritis. Note incidental ﬁnding of an area of partially sclerotic bone reﬂecting a
metaphyseal femoral bone infarct (white arrows). B. Soft tissue opacities consistent with typical gout tophi are seen in the periarticular region of this knee (large arrows). In addition
minor bony erosions are detected (small white arrows). C. Separate patellar ossicle (arrows) represents bipartite patella, an anatomical variant not to be mistaken for a fracture. D. In
contrast, a sclerotic band in the metaphysal tibia of this knee joint represents healing response at the fracture site (arrows).
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Fig. 14. Other arthropathies. A. Anterioreposterior radiograph shows a markedly deformed knee joint with collapse of the medial tibial plateau. Note large subchondral cystic areas
in the periarticular femur and tibia (arrows). B. Lateral radiograph conﬁrms severe osteoarthritic changes with joint deformity. A deﬁnite diagnosis cannot be established based on
radiograph alone, but joint deformity is consistent with RPOA Type II and thus, a diagnosis of exclusion. C. The additional coronal fat suppressed T2-weighted MRI shows a large
mass of diffuse hypointensity reﬂecting susceptibility artifacts (asterisks). D. Corresponding sagittal T1-weighted MRI conﬁrms hypointense mass-like lesion within the joint cavity
(asterisk). This is the typical appearance of PVNS characterized by hemosiderin deposits.
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Fig. 15. Tumor-like and cystic lesions may or may not be a diagnosis of exclusion depending on size, bengin or malignant appearance and particularly based on potential risk of
fracture. A. Radiograph shows typical multilobulated and expansive appearance of ﬁbrous dysplasia, a benign condition. As lesion occupies a large proportion of tibia this represents
a ﬁnding of exlcusion. B. Metaphyseal cystic lesion with sclerotic rim (arrows). No deﬁnite diagnosis can be established based on X-ray alone but lesion appears to be deﬁnitely
benign. However, as lesion in its entirety occupies more than 1/3 of bone in both views, the a.p. and lateral, this would be considered a lesion of exclusion due to increased racture
risk. C. Typical ﬁnding of a non-ossifying ﬁbroma of the metaphyseal femur. Lesion is well-demarcated and shows a sclerotic rim (arrows). The lateral radiograph showed that lesion
only occupied the posterior quarter of the femur, and thus, this would not be a diagnosis of exclusion. D. Typical ﬁnding of a tibial metaphyseal enchondroma with multilobulated
popcorn-like appearance (arrows). Benign incidental ﬁnding and no diagnosis for exclusion.
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Fig. 16. A. Typical ﬁnding of a malignant bone tumor with spiculated cortex and partly lytic, partly sclerotic appearance. Finding represents an osteosarcoma, a deﬁnite diagnosis for
exclusion. B. Systemic disease may be a reason for exclusion. This example shows severe joint destruction due to repetitive intraarticular hemorrhage in a hemophilic patient. C.
Severe malalignment is not uniformly deﬁned but may be a diagnosis for patient exclusion at eligibility. Example shows 10 varus malalignement as measured using the anatomical
axis. D. Severe valgus malalignment of 11 is shown in this example, which may be reason for ineligibility.
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